Drs Shubrook and Chamberlain discuss cardiovascular risk reduction associated with SGLT-2 inhibitors and GLP-1 agonists in T2D, and advise clinicians to 'be aware.'
Dr Tyree Winters stresses the importance of identifying at-risk kids and screening often, as much as annually, to be sure that early-stage type 2 diabetes is not missed.
Drs O'Donoghue and McGuire discuss the data on the various SGLT2 inhibitors and GLP1 receptor agonists and when to consider prescribing them to your patients with diabetes.
The American Heart Association sessions featured two new analyses from the FOURIER trial, which prompted a discussion on the cost-effectiveness of PCSK9 inhibitor lipid-lowering therapy.
Dr Walton-Shirley reviews the key updates in the 2017 ACC/AHA guidelines for the Prevention, Detection, Evaluation and Management of High Blood Pressure with the guideline chair.
The FreeStyle Libre, a newly approved device for continuous glucose monitoring, is a big advance for people with diabetes who want to avoid finger sticks, says Dr Anne Peters.
Dr JoAnn Manson comments on a recent study revealing that gestational diabetes is like a window into a woman's future risk for cardiovascular disease and type 2 diabetes.
Research presented at EASD 2017 shows that dapagliflozin may reduce insulin requirements with a low risk of adverse effects in patients with type 1 diabetes.